We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company


  Silver Produces reagents for medical laboratory diagnostics, including test systems for the determination of various antibod... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Feb 2023 - 09 Feb 2023

ELISAs Reliably Detect Anti-CCHFV Antibodies in Acute Infections

By LabMedica International staff writers
Posted on 19 Jan 2023
Print article
The EUROIMMUN Anti-CCHFV IgM and IgG ELISAs are based on recombinant viral nucleoprotein (Photo courtesy of EUROIMMUN)
The EUROIMMUN Anti-CCHFV IgM and IgG ELISAs are based on recombinant viral nucleoprotein (Photo courtesy of EUROIMMUN)

Crimean-Congo haemorrhagic fever (CCHF) is a life-threatening tick-borne viral disease included in the WHO priorities for research and product development for early diagnostics. EUROIMMUN (Lübeck, Germany), a PerkinElmer, Inc. (Waltham, MA; USA) company, has developed and subsequently evaluated ELISAs for the detection of specific IgM and IgG antibodies against the causative virus (CCHFV).

The EUROIMMUN Anti-CCHFV IgM and IgG ELISAs are based on recombinant viral nucleoprotein with the N-protein being the major target of the immune response. N-specific IgM is detectable after a median of 2-3 days after the onset of symptoms, followed by IgG 1-2 days later. The diagnostic performance of the novel commercial ELISAs was evaluated against established CE-marked tests. These were the EUROIMMUN CCHFV Mosaic 2 IgM and IgG indirect immunofluorescence assays (IFA), which served as reference tests, and IgM and IgG ELISAs from another manufacturer.

The EUROIMMUN Anti-CCHFV IgM and IgG ELISAs both yielded a higher sensitivity (IgM 98.0%, IgG 47.1%) than the other commercial ELISAs (IgM 95.9%, IgG 35.3%), as determined in 49 serum samples from patients with acute-phase CCHFV infection. The lower sensitivity of both IgG ELISAs compared to IFA could be attributed to varying antigen presentation between the two techniques and the study panel of acute-phase samples. However, the main value of IgG analysis is in disease monitoring and epidemiological surveillance. The EUROIMMUN IgG ELISA had previously demonstrated a sensitivity of 98.8% in patients with subsided CCHF.

The specificity of the EUROIMMUN IgM ELISA was slightly higher (86.4%) than that of the other ELISA (84.7%), as evaluated in 89 sera from control patients, healthy blood donors and patients with hantavirus or sandfly fever infections. For IgG, both assays demonstrated a specificity of 100%. The authors have summarized that the ELISAs from the two manufacturers showed a substantial qualitative agreement and a very strong positive correlation of quantitative results for both IgM and IgG. They concluded that the EUROIMMUN Anti-CCHFV ELISAs are standardised and easy-to-use tools that reliably support identification of acute CCHF cases.

The study was performed in a population in Türkiye, which has the highest number of laboratory-confirmed CCHF cases in the world. The endemic region of CCHFV encompasses countries in Africa, the Balkans, the Middle East and Asia that lie within the geographical habitat of the principal tick vector, namely ticks of the genus Hyalomma. Due to the non-availability of CCHF vaccine, the management of local outbreaks is dependent upon rapid identification of cases and appropriate infection control measures. Since ELISAs are less complex as compared to other serological methods, they are highly suitable for use in on-site laboratories involved in outbreak assistance.

Gold Supplier
Hematology Workflow Solution
FOB Rapid Test Strip
FOB Rapid Test
Gold Supplier
Specimen Collection & Transport
Specimen Collection & Transport Devices
Rapid Fecal Occult Blood (FOB) Test
Advanced Quality Rapid FOB Test

Print article



view channel
Image: Histopathology of Langerhans cell histiocytosis: The variation in nuclear contours of these cells is evident in this lesion. Classic `kidney bean` nuclei of Langerhans cells with a central groove are present (Photo courtesy of John Lazarchick, MD)

Cooperativity Between Myeloid Lineages Promotes Langerhans Cell Histiocytosis Pathology

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia seen in children and adults who present with lesions composed of pathologic variants of myeloid cells that share certain phenotypic... Read more


view channel
Image: Medical illustration of Carbapenem-resistant Enterobacteriacea (Photo courtesy of CDC, Stephanie Rossow)

Breakthrough Test Enables Targeted Antibiotic Therapy for Various Enterobacter Species

Bacteria of the Enterobacter genus are considered to be the most dangerous bacteria linked to hospital infections across the world. Some of their representatives demonstrate high resistance to commonly-used... Read more


view channel
Image: Flexible copper sensor made cheaply from ordinary materials (Photo courtesy of University of São Paulo)

Low-Cost Portable Sensor Detects Heavy Metals in Sweat

Heavy metals like lead and cadmium can be found in batteries, cosmetics, food and many other things that have become a part of daily life. However, they become toxic if they accumulate in the human body... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.